Literature DB >> 17699663

Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice.

Heather A Boger1, Lawrence D Middaugh, Kennerly S Patrick, Sammanda Ramamoorthy, Emily D Denehy, Haojie Zhu, Alejandra M Pacchioni, Ann-Charlotte Granholm, Jacqueline F McGinty.   

Abstract

Methamphetamine abuse in young adults has long-term deleterious effects on brain function that are associated with damage to monoaminergic neurons. Administration of glial cell line-derived neurotrophic factor (GDNF) protects dopamine neurons from the toxic effects of methamphetamine in animal models. Therefore, we hypothesized that a partial GDNF gene deletion would increase the susceptibility of mice to methamphetamine neurotoxicity during young adulthood and possibly increase age-related deterioration of behavior and dopamine function. Two weeks after a methamphetamine binge (4 x 10 mg/kg, i.p., at 2 h intervals), GDNF(+/-) mice had a significantly greater reduction of tyrosine hydroxylase immunoreactivity in the medial striatum, a proportionally greater depletion of dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the striatum, and a greater increase in activated microglia in the substantia nigra than wild-type mice. At 12 months of age, methamphetamine-treated GDNF(+/-) mice exhibited less motor activity and lower levels of tyrosine hydroxylase-immunoreactivity, dopamine, DOPAC, and serotonin than wild-type mice. Greater striatal dopamine transporter activity in GDNF(+/-) mice may underlie their differential response to methamphetamine. These data suggest the possibility that methamphetamine use in young adults, when combined with lower levels of GDNF throughout life, may precipitate the appearance of parkinsonian-like behaviors during aging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699663      PMCID: PMC2698457          DOI: 10.1523/JNEUROSCI.1067-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  60 in total

1.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

2.  Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome.

Authors:  Ann-Charlotte E Granholm; Kerstin A Ford; Lynn A Hyde; Heather A Bimonte; Christopher L Hunter; Matt Nelson; David Albeck; Linda A Sanders; Elliott J Mufson; Linda S Crnic
Journal:  Physiol Behav       Date:  2002-11

3.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; M Leonido-Yee; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; J Logan; C Wong; E N Miller
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

Review 4.  Imaging end points for monitoring neuroprotection in Parkinson's disease.

Authors:  David J Brooks
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

Review 5.  The role of the locus coeruleus in the development of Parkinson's disease.

Authors:  M Gesi; P Soldani; F S Giorgi; A Santinami; I Bonaccorsi; F Fornai
Journal:  Neurosci Biobehav Rev       Date:  2000-08       Impact factor: 8.989

6.  Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion.

Authors:  D M Yurek; A Fletcher-Turner
Journal:  Brain Res       Date:  2001-02-09       Impact factor: 3.252

Review 7.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption.

Authors:  Taizo Kita; George C Wagner; Toshikatsu Nakashima
Journal:  J Pharmacol Sci       Date:  2003-07       Impact factor: 3.337

8.  Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations.

Authors:  Jeffrey N Joyce; Lynn Renish; Tracy Osredkar; Jon M Walro; Jan Kucera; Dean E Dluzen
Journal:  Synapse       Date:  2004-04       Impact factor: 2.562

9.  Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence.

Authors:  Gene-Jack Wang; Nora D Volkow; Linda Chang; Eric Miller; Mark Sedler; Robert Hitzemann; Wei Zhu; Jean Logan; Yeming Ma; Joanna S Fowler
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

10.  The noradrenergic system of aged GDNF heterozygous mice.

Authors:  V Zaman; Z Li; L Middaugh; S Ramamoorthy; B Rohrer; M E Nelson; A C Tomac; B J Hoffer; G A Gerhardt; A Ch Granholm
Journal:  Cell Transplant       Date:  2003       Impact factor: 4.064

View more
  40 in total

Review 1.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

Review 2.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

3.  Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.

Authors:  Erin R Hascup; Sarah O Broderick; Mary K Russell; Yimin Fang; Andrzej Bartke; Heather A Boger; Kevin N Hascup
Journal:  J Neurochem       Date:  2019-01-03       Impact factor: 5.372

4.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

Review 5.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

Review 6.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

7.  Methamphetamine augment HIV-1 Tat mediated memory deficits by altering the expression of synaptic proteins and neurotrophic factors.

Authors:  Anantha Ram Nookala; Daniel C Schwartz; Nitish S Chaudhari; Alexy Glazyrin; Edward B Stephens; Nancy E J Berman; Anil Kumar
Journal:  Brain Behav Immun       Date:  2018-05-02       Impact factor: 7.217

8.  The Role of Glial Cells in Drug Abuse.

Authors:  Jose Javier Miguel-Hidalgo
Journal:  Curr Drug Abuse Rev       Date:  2009

9.  Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene.

Authors:  Heather A Boger; Lawrence D Middaugh; Vandana Zaman; Barry Hoffer; Ann-Charlotte Granholm
Journal:  Brain Res       Date:  2008-09-16       Impact factor: 3.252

10.  Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum.

Authors:  Jean Lud Cadet; Michael T McCoy; Ning Sheng Cai; Irina N Krasnova; Bruce Ladenheim; Genevieve Beauvais; Natascha Wilson; William Wood; Kevin G Becker; Amber B Hodges
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.